Arabic Arabic English English French French German German
dark

Sparx Therapeutics Is Building its First Commercial Manufacturing Facility for Its Antibody Drug Production

Sparx Therapeutics announced a plan to build a 1,200,000-square-foot manufacturing facility in Yangzhou, China, inching closer to becoming a commercial stage biopharma. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Nyxoah Announces Closing of Nasdaq Initial Public Offering and Underwriters’ Full Exercise of Option to Purchase Additional Shares

Next Post

Updated results from phase 3 OCEAN study shows melflufen met primary endpoint of superior PFS – Overall Survival data lead to partial clinical hold

Related Posts
Total
0
Share